mayo 30 2023

Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition of the US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals

Share
Paris – Mayer Brown advised the SERB group, a global specialty pharmaceutical group, on the structuring of the acquisition of the exclusive US rights to bentracimab, a ticagrelor reversal agent, from SFJ Pharmaceuticals, a global drug development company. 

Mayer Brown advised SERB Pharmaceuticals on the structuring of the acquisition with a team composed of Partner Olivier Parawan, Associates Sarah Rahmoun and Julia Videau in Paris and Partner Remmelt Reigersman in San Francisco. 

Servicios e Industrias Relacionadas

Servicios

Industrias

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe